Nanomedicine

被引:0
作者
Alexiou, C. [1 ]
Tietze, R. [1 ]
Schreiber, E. [1 ]
Lyer, S. [1 ]
机构
[1] Univ Klinikum Erlangen, Hals Nasen Ohren Klin, Sekt Expt Onkol & Nanomed Else Kroner Fresenius S, D-91054 Erlangen, Germany
关键词
Nanomedicine; Nanoparticles; Drug delivery; Magnetic drug targeting; Hyperthermia; FLUID HYPERTHERMIA MFH; LYMPH-NODE METASTASES; MAGNETIC NANOPARTICLES; CANCER-TREATMENT; DRUG; TEMPERATURE; CARCINOMA; PROSTATE; BIODISTRIBUTION; MITOXANTRONE;
D O I
10.1007/s00103-010-1097-9
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The application of nanotechnology for the treatment, diagnosis, and monitoring of illnesses is summarized under the term nanomedicine. A particularly promising application is attributed to nanoparticular drug delivery systems. The goal of these new carrier systems is the selective enrichment of active substances in diseased tissue structures, an increase in bioavailability, the decrease of the active substance degradation and, above all, the reduction and/or avoidance of unwanted side effects. Apart from numerous nanosystems acting as carriers, the use of iron oxide nanoparticles has to be particularly emphasized. On the one hand, those particles are the carriers of the active substance and, on the other hand, can also be visualized with conventional imaging techniques (x-ray tomography, magnetic resonance imaging), called theranostic. In addition, they can be used for hyperthermia, another important supporting pillar of nanomedicine. Both procedures should lead to a personalized and goal-oriented therapy, which is of special medical and socioeconomic importance in view of the increasing number of cancer patients worldwide.
引用
收藏
页码:839 / 845
页数:7
相关论文
共 50 条
[1]   Magnetic Drug Targeting - A new approach in locoregional tumortherapy with chemotherapeutic agents. Experimental animal studies [J].
Alexiou C. ;
Jurgons R. ;
Schmid R. ;
Erhardt W. ;
Parak F. ;
Bergemann C. ;
Iro H. .
HNO, 2005, 53 (7) :618-622
[2]   Magnetic drug targeting - Biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment [J].
Alexiou, C ;
Jurgons, R ;
Schmid, RJ ;
Bergemann, C ;
Henke, J ;
Erhardt, W ;
Huenges, E ;
Parak, F .
JOURNAL OF DRUG TARGETING, 2003, 11 (03) :139-149
[3]   Magnetic drug targeting: biodistribution and dependency on magnetic field strength [J].
Alexiou, C ;
Schmidt, A ;
Klein, R ;
Hulin, P ;
Bergemann, C ;
Arnold, W .
JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, 2002, 252 (1-3) :363-366
[4]  
Alexiou C, 2000, CANCER RES, V60, P6641
[5]   Magnetic mitoxantrone nanoparticle detection by histology, X-ray and MRI after magnetic tumor targeting [J].
Alexiou, C ;
Arnold, W ;
Hulin, P ;
Klein, RJ ;
Renz, H ;
Parak, FG ;
Bergemann, C ;
Lübbe, AS .
JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, 2001, 225 (1-2) :187-193
[6]   A high field gradient magnet for magnetic drug targeting [J].
Alexiou, Christoph ;
Diehl, Dirk ;
Henninger, Peter ;
Iro, Heinrich ;
Roeckelein, Rudolf ;
Schmidt, Wolfgang ;
Weber, Horst .
IEEE TRANSACTIONS ON APPLIED SUPERCONDUCTIVITY, 2006, 16 (02) :1527-1530
[7]   Targeting cancer cells: magnetic nanoparticles as drug carriers [J].
Alexiou, Christoph ;
Schmid, Roswitha J. ;
Jurgons, Roland ;
Kremer, Marcus ;
Wanner, Gerhard ;
Bergemann, Christian ;
Huenges, Ernst ;
Nawroth, Thomas ;
Arnold, Wolfgang ;
Parak, Fritz G. .
EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS, 2006, 35 (05) :446-450
[8]  
ALKSNE JF, 1966, SURGERY, V60, P212
[9]  
[Anonymous], OPP RISKS NAN REP CO
[10]   Targeting the prostate for destruction through a vascular address [J].
Arap, W ;
Haedicke, W ;
Bernasconi, M ;
Kain, R ;
Rajotte, D ;
Krajewski, S ;
Ellerby, HM ;
Bredesen, DE ;
Pasqualini, R ;
Ruoslahti, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (03) :1527-1531